<p>Prime Medicine, Inc.（纽约证券交易所代码：PRME - 获取免费报告）在周二的午盘交易中下跌了 6.7%。该股票最低交易价格为 4.16 美元，最后交易价格为 4.20 美元。在交易中，共交易了 1,029,369 股，较平均交易量 2,403,093 股下降了 57%。该股票之前的收盘价为 4.50 美元。</p>
<p>获取 <strong>Prime Medicine</strong> 警报：</p>
<h2>分析师评级变动</h2>
<ul>
<li>2024 年值得关注的 2 只基因编辑股票</li>
</ul>
<p>几家研究公司最近对 PRME 进行了评估。Chardan Capital 将 Prime Medicine 的目标价格从 16.00 美元下调至 12.00 美元，并在 5 月 19 日的报告中对该股票给予了 “买入” 评级。JMP Securities 将 Prime Medicine 的目标价格从 10.00 美元下调至 6.00 美元，并在 5 月 20 日的报告中对该股票给予了 “市场表现优于大盘” 的评级。花旗集团在 5 月 27 日的报告中重申了 “中性” 评级，并将 Prime Medicine 的目标价格设定为 1.50 美元（之前为 10.00 美元）。HC Wainwright 在 5 月 20 日的报告中将 Prime Medicine 的评级从 “买入” 下调至 “中性”。最后，Wedbush 在 7 月 16 日的报告中重申了 “表现优于大盘” 的评级，并对 Prime Medicine 的股票设定了 8.00 美元的价格目标。一位研究分析师对该股票给予了卖出评级，三位给予了持有评级，四位给予了买入评级，还有一位给予了强烈买入评级。根据 MarketBeat.com 的数据，Prime Medicine 目前的平均评级为 “适度买入”，共识目标价格为 9.25 美元。</p>
<p><strong>获取我们关于 Prime Medicine 的最新报告</strong></p>
<h2>Prime Medicine 下跌 3.0%</h2>
<p>该股票的市值为 5.8708 亿美元，市盈率为-2.14，贝塔值为 2.38。该公司的 50 日简单移动平均线为 2.88 美元，200 日简单移动平均线为 2.31 美元。</p>
<h2>Prime Medicine 内部活动</h2>
<p>在其他 Prime Medicine 的新闻中，主要股东 David R. Liu 在 6 月 23 日的交易中购买了 21,000 股该公司的股票。该股票的平均购买成本为每股 2.16 美元，总价值为 45,360.00 美元。完成购买后，该内部人士直接持有公司 20,219,945 股，价值约为 43,675,081.20 美元。这笔交易代表了他们持股比例的 0.10% 的增加。该购买在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，主要股东 Arch Venture Partners Xii, Llc 在 8 月 1 日的交易中购买了 3,030,300 股 Prime Medicine 股票。该股票的平均购买价格为每股 3.30 美元，总价值为 9,999,990.00 美元。交易完成后，该内部人士持有公司 6,230,300 股，价值为 20,559,990 美元。这代表了他们持股比例的 94.70% 的增加。该购买的披露信息可以在这里找到。内部人士在上个季度购买了价值 10,110,240 美元的 3,093,300 股公司股票。内部人士持有公司 22.93% 的股票。</p>
<h2>Prime Medicine 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近买卖了 PRME 的股票。Westwood Holdings Group Inc.在第四季度将其在 Prime Medicine 的持股比例增加了 96.5%。Westwood Holdings Group Inc.目前持有 883,129 股该公司的股票，价值为 2,579,000 美元，此前在该期间又购买了 433,653 股。Walleye Capital LLC 在第四季度将其在 Prime Medicine 的持股比例提高了 272.5%。Walleye Capital LLC 目前持有 403,739 股该公司的股票，价值为 1,179,000 美元，此前在上个季度又购买了 295,365 股。AQR Capital Management LLC 在第一季度将其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前持有 243,795 股该公司的股票，价值为 485,000 美元，此前在上个季度又购买了 227,749 股。T. Rowe Price Investment Management Inc.在第四季度将其在 Prime Medicine 的持股比例提高了 4.5%。T. Rowe Price Investment Management Inc.目前持有 3,977,828 股该公司的股票，价值为 11,616,000 美元，此前在上个季度又购买了 170,541 股。最后，Susquehanna Fundamental Investments LLC 在第四季度购买了价值 423,000 美元的 Prime Medicine 新股份。目前 70.37% 的股票由机构投资者和对冲基金持有。</p>
<h2>Prime Medicine 公司简介</h2>
<p>（获取免费报告）</p>
<p>Prime Medicine, Inc.是一家生物技术公司，通过部署基因编辑技术提供遗传疗法，以应对各种疾病。该公司提供 Prime Editors，包含 Cas 蛋白和逆转录酶的融合体的 Prime Editor 蛋白；以及 pegRNA，旨在将 Prime Editor 定位到特定的基因组位置，并提供用于对目标 DNA 序列进行所需编辑的模板。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票超过 Prime Medicine</li>
<li>标普 500 股票向投资者传达了什么市场信息？</li>
<li>应用数字：为什么看涨押注的激增预示着一个新时代</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>Palantir 股票在超预期财报后飙升</li>
<li>如何投资 FAANG 股票</li>
<li>亚马逊进入修正区：是时候恐慌还是勇敢？</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们现在购买，以便在更广泛的市场注意到之前……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRME

<p>Prime Medicine（纽约证券交易所代码：PRME）股价下跌 6.7%，至 4.20 美元，交易量较平均水平下降 57%。分析师们已调整目标价格，Chardan Capital 将其目标价从 16 美元下调至 12 美元，而花旗集团则设定了 1.50 美元的新目标。内部交易出现显著购买，增加了持股比例。机构投资者持有 70.37% 的股份。该公司专注于使用基因编辑技术进行基因疗法，市值为 5.8708 亿美元，市盈率为-2.14</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report) traded down 6.7% during mid-day trading on Tuesday . The stock traded as low as $4.16 and last traded at $4.20. 1,029,369 shares were traded during trading, a decline of 57% from the average session volume of 2,403,093 shares. The stock had previously closed at $4.50.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（纽约证券交易所代码：PRME - 获取免费报告）在周二的午盘交易中下跌了 6.7%。该股票最低交易价格为 4.16 美元，最后交易价格为 4.20 美元。在交易中，共交易了 1,029,369 股，较平均交易量 2,403,093 股下降了 57%。该股票之前的收盘价为 4.50 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 警报：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年值得关注的 2 只基因编辑股票</li>
</ul>
</div><p>Several research firms recently weighed in on PRME. Chardan Capital reduced their target price on shares of Prime Medicine from $16.00 to $12.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, May 19th. JMP Securities reduced their target price on shares of Prime Medicine from $10.00 to $6.00 and set a &#34;market outperform&#34; rating on the stock in a report on Tuesday, May 20th. Citigroup restated a &#34;neutral&#34; rating and set a $1.50 target price (down previously from $10.00) on shares of Prime Medicine in a report on Tuesday, May 27th. HC Wainwright lowered shares of Prime Medicine from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Tuesday, May 20th. Finally, Wedbush reiterated an &#34;outperform&#34; rating and issued a $8.00 price objective on shares of Prime Medicine in a report on Wednesday, July 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Prime Medicine presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.25.</p>
<div class="lb-trans"><p>几家研究公司最近对 PRME 进行了评估。Chardan Capital 将 Prime Medicine 的目标价格从 16.00 美元下调至 12.00 美元，并在 5 月 19 日的报告中对该股票给予了 “买入” 评级。JMP Securities 将 Prime Medicine 的目标价格从 10.00 美元下调至 6.00 美元，并在 5 月 20 日的报告中对该股票给予了 “市场表现优于大盘” 的评级。花旗集团在 5 月 27 日的报告中重申了 “中性” 评级，并将 Prime Medicine 的目标价格设定为 1.50 美元（之前为 10.00 美元）。HC Wainwright 在 5 月 20 日的报告中将 Prime Medicine 的评级从 “买入” 下调至 “中性”。最后，Wedbush 在 7 月 16 日的报告中重申了 “表现优于大盘” 的评级，并对 Prime Medicine 的股票设定了 8.00 美元的价格目标。一位研究分析师对该股票给予了卖出评级，三位给予了持有评级，四位给予了买入评级，还有一位给予了强烈买入评级。根据 MarketBeat.com 的数据，Prime Medicine 目前的平均评级为 “适度买入”，共识目标价格为 9.25 美元。</p>
</div><p><strong>Get Our Latest Report on Prime Medicine</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Prime Medicine 的最新报告</strong></p>
</div><h2>Prime Medicine Trading Down 3.0%</h2>
<div class="lb-trans"><h2>Prime Medicine 下跌 3.0%</h2>
</div><p>The stock has a market cap of $587.08 million, a P/E ratio of -2.14 and a beta of 2.38. The firm's 50-day simple moving average is $2.88 and its 200 day simple moving average is $2.31.</p>
<div class="lb-trans"><p>该股票的市值为 5.8708 亿美元，市盈率为-2.14，贝塔值为 2.38。该公司的 50 日简单移动平均线为 2.88 美元，200 日简单移动平均线为 2.31 美元。</p>
</div><h2>Insider Activity at Prime Medicine</h2>
<div class="lb-trans"><h2>Prime Medicine 内部活动</h2>
</div><p>In other Prime Medicine news, major shareholder David R. Liu bought 21,000 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The stock was acquired at an average cost of $2.16 per share, with a total value of $45,360.00. Following the completion of the purchase, the insider directly owned 20,219,945 shares in the company, valued at approximately $43,675,081.20. This trade represents a 0.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Arch Venture Partners Xii, Llc purchased 3,030,300 shares of Prime Medicine stock in a transaction that occurred on Friday, August 1st. The stock was purchased at an average price of $3.30 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 6,230,300 shares in the company, valued at $20,559,990. This represents a 94.70% increase in their position. The disclosure for this purchase can be found here. Insiders bought 3,093,300 shares of company stock valued at $10,110,240 over the last quarter. Insiders own 22.93% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Prime Medicine 的新闻中，主要股东 David R. Liu 在 6 月 23 日的交易中购买了 21,000 股该公司的股票。该股票的平均购买成本为每股 2.16 美元，总价值为 45,360.00 美元。完成购买后，该内部人士直接持有公司 20,219,945 股，价值约为 43,675,081.20 美元。这笔交易代表了他们持股比例的 0.10% 的增加。该购买在向 SEC 提交的文件中披露，文件可通过此链接获取。此外，主要股东 Arch Venture Partners Xii, Llc 在 8 月 1 日的交易中购买了 3,030,300 股 Prime Medicine 股票。该股票的平均购买价格为每股 3.30 美元，总价值为 9,999,990.00 美元。交易完成后，该内部人士持有公司 6,230,300 股，价值为 20,559,990 美元。这代表了他们持股比例的 94.70% 的增加。该购买的披露信息可以在这里找到。内部人士在上个季度购买了价值 10,110,240 美元的 3,093,300 股公司股票。内部人士持有公司 22.93% 的股票。</p>
</div><h2>Institutional Trading of Prime Medicine</h2>
<div class="lb-trans"><h2>Prime Medicine 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of PRME. Westwood Holdings Group Inc. grew its position in shares of Prime Medicine by 96.5% during the 4th quarter. Westwood Holdings Group Inc. now owns 883,129 shares of the company's stock worth $2,579,000 after buying an additional 433,653 shares during the period. Walleye Capital LLC lifted its stake in Prime Medicine by 272.5% in the fourth quarter. Walleye Capital LLC now owns 403,739 shares of the company's stock valued at $1,179,000 after buying an additional 295,365 shares in the last quarter. AQR Capital Management LLC lifted its stake in Prime Medicine by 1,419.4% in the first quarter. AQR Capital Management LLC now owns 243,795 shares of the company's stock valued at $485,000 after buying an additional 227,749 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Prime Medicine by 4.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,977,828 shares of the company's stock valued at $11,616,000 after buying an additional 170,541 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Prime Medicine in the fourth quarter worth $423,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了 PRME 的股票。Westwood Holdings Group Inc.在第四季度将其在 Prime Medicine 的持股比例增加了 96.5%。Westwood Holdings Group Inc.目前持有 883,129 股该公司的股票，价值为 2,579,000 美元，此前在该期间又购买了 433,653 股。Walleye Capital LLC 在第四季度将其在 Prime Medicine 的持股比例提高了 272.5%。Walleye Capital LLC 目前持有 403,739 股该公司的股票，价值为 1,179,000 美元，此前在上个季度又购买了 295,365 股。AQR Capital Management LLC 在第一季度将其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前持有 243,795 股该公司的股票，价值为 485,000 美元，此前在上个季度又购买了 227,749 股。T. Rowe Price Investment Management Inc.在第四季度将其在 Prime Medicine 的持股比例提高了 4.5%。T. Rowe Price Investment Management Inc.目前持有 3,977,828 股该公司的股票，价值为 11,616,000 美元，此前在上个季度又购买了 170,541 股。最后，Susquehanna Fundamental Investments LLC 在第四季度购买了价值 423,000 美元的 Prime Medicine 新股份。目前 70.37% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.是一家生物技术公司，通过部署基因编辑技术提供遗传疗法，以应对各种疾病。该公司提供 Prime Editors，包含 Cas 蛋白和逆转录酶的融合体的 Prime Editor 蛋白；以及 pegRNA，旨在将 Prime Editor 定位到特定的基因组位置，并提供用于对目标 DNA 序列进行所需编辑的模板。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>Applied Digital: Why a Surge in Bullish Bets Signals a New Era</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Palantir Stock Soars After Blowout Earnings Report</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Amazon Enters Correction Zone: Time to Panic or Be Brave?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Prime Medicine</li>
<li>标普 500 股票向投资者传达了什么市场信息？</li>
<li>应用数字：为什么看涨押注的激增预示着一个新时代</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>Palantir 股票在超预期财报后飙升</li>
<li>如何投资 FAANG 股票</li>
<li>亚马逊进入修正区：是时候恐慌还是勇敢？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们现在购买，以便在更广泛的市场注意到之前……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Prime Medicine（NYSE 代码：PRME）股价下跌 6.7% - 以下是事件的经过